AZ-AXWAY
Axway (NYSE Euronext:AXW.PA), a market leader in governing the flow of data, today announced its increased presence in Australia and New Zealand by expanding its footprint in the Asia Pacific region and opening a new office in Melbourne, Australia. To accompany this expansion, Colman McCaffery, formerly Layer 7 Technologies’ Regional Sales Director, joins Axway as Vice President, Sales & Operations, Australia New Zealand to lead the successful development of the company and respond to the increasing demand for the Axway 5 Suite in the region. This strategic investment will strengthen Axway’s capabilities with 20 talented sales and technical experts, and will enable Axway to roll out its solutions more efficiently. With an existing customer base of more than 100 organizations, Axway 5 Suite offers the unique ability to combine application integration with B2B , MFT and API management to help organizations govern the flow of data across enterprises, cloud and mobile.
Colman McCaffery joins Axway with more than 20 years of experience in sales, implementation and management of transformational IT solutions and technologies. During the past 15 years, McCaffery has developed a strong track record in sales, development and integration of API, SOA , mobility and cloud-based software infrastructure. In his new role, McCaffrey will drive sales productivity and customer satisfaction for Axway 5 Suite in alignment with the company’s mission in Australia and New Zealand.
“This is a key step in the development of our global strategy. We are constantly expanding our geographical footprint to strengthen our market position and the delivery of our solutions to our customers,” said Christophe Fabre, CEO, Axway. “With the addition of Colman’s expertise and talent, we hope to grow our customer base in line with the clear demand for data flow governance solutions in Australia and New Zealand. As regional businesses take advantage of our broad portfolio, including the Axway 5 Suite, they will open themselves to new opportunities in the marketplace, giving them improved business productivity and the competitive edge in their respective fields.”
“Axway’s decision to expand its regional presence here is a testimony of their commitment and engagement with their customers,” indicated Ian Gibson, CIO of Superchoice, an Axway customer. “I am delighted to have chosen Axway as a global B2B software specialist to help with our strategy of governing the flow of superannuation data. Using the Axway 5 Suite, we can consolidate all of our disparate point-to-point connections into one platform, both simplifying and improving operations management while reducing the cost of managing customers.”
As businesses continue to be inundated by data, particularly from the explosive growth of cloud and mobile, IT departments’ key focus will not only be how to secure data, but how to control, monitor and govern it. Combining Axway’s unique API Management solution with its core B2B, MFT and SOA governance capabilities allows Axway to provide solutions one step further than traditional integration middleware products by governing data flows across the enterprise and beyond the edge to include customers and trading partners.
For more information about Axway’s products and solutions: http://www.axway.com/products-solutions
Follow Axway on Twitter @Axway
About Axway
Axway (NYSE Euronext:AXW.PA), a market leader in governing the flow of data, is a global software company with more than 11,000 public- and private-sector customers in 100 countries. For more than a decade, Axway has empowered leading organizations around the world with proven solutions that help manage business-critical interactions through the exchange of data flowing across the enterprise, among B2B communities, cloud and mobile devices. Our award-winning solutions span business-to-business integration, managed file transfer, API and identity management, and email security– offered on premise and in the Cloud with professional and managed services. Axway is registered in France with headquarters in the United States and offices in 19 countries. www.axway.com
About Axway 5 Suite
Axway 5 Suite offers control and optimization of the flow of data through integration, visibility, policy, security and reliability to govern business-to-business interactions, communities, systems and data types — within and beyond the enterprise edge.
Contact:
Media
Blanc & Otus
Bill Rundle, 415-856-5104
brundle@blancandotus.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum